Vékony Bálint, Nyirő Gábor, Butz Henriett, Szeredás Bálint Kende, Tóth Viktória, Ferdinandy Peter, Patócs Attila, Igaz Peter
Endocr Relat Cancer. 2025 Jun 17;32(6). doi: 10.1530/ERC-25-0045. Print 2025 Jun 1.
The differentiation of benign and malignant adrenocortical tumors is of major clinical relevance. Circulating microRNAs (miRNAs) hold promise as blood-borne biomarkers of adrenocortical cancer (ACC). There are, however, many difficulties with their use, including technical and biological standardization challenges. Our aim was to evaluate the interchangeability of quantitative polymerase chain reaction (qPCR) and digital PCR (dPCR) for measuring circulating miRNAs and to investigate whether K2- and K3-EDTA as anticoagulants influence the measurements. Blood samples were drawn simultaneously from 20 participants into K2- and K3-EDTA tubes. Three miRNAs shown to be associated with ACC (miR-483-5p, miR-210-3p, miR-21-5p), together with two controls (miR-16-5p, cel-miR-39-3p), were analyzed using RT-qPCR and dPCR. qPCR and dPCR results showed different correlations in K2- and K3-EDTA samples, with K2 performing better regarding ΔCt values. Moreover, proportional biases related to low or high miRNA expressions between the two methods were observed. In qPCR measurements, K3-EDTA samples showed larger standard deviations, particularly for cel-miR-39. While raw Ct values differed between K2- and K3-EDTA only for miR-483-5p, ΔCt values showed statistically significant differences across all miRNAs except for miR-483-5p. dPCR results were not affected by the choice of anticoagulant. In conclusion, this is the first study demonstrating that dPCR and qPCR results are not easily interchangeable for circulating miRNA, particularly for abundant or rare miRNAs, making cross-validation studies challenging. K2- and K3-EDTA could potentially influence qPCR outcomes, underscoring the need for standardized protocols. A consensus-based methodology could improve reproducibility, enhancing miRNA-based biomarker utility in adrenocortical tumor diagnostics.
良性和恶性肾上腺皮质肿瘤的鉴别具有重要的临床意义。循环微小RNA(miRNA)有望成为肾上腺皮质癌(ACC)的血液生物标志物。然而,其应用存在许多困难,包括技术和生物学标准化挑战。我们的目的是评估定量聚合酶链反应(qPCR)和数字PCR(dPCR)在测量循环miRNA方面的互换性,并研究作为抗凝剂的K2-和K3-乙二胺四乙酸(EDTA)是否会影响测量结果。从20名参与者中同时采集血液样本,分别放入K2-和K3-EDTA管中。使用逆转录定量PCR(RT-qPCR)和dPCR分析了三种已显示与ACC相关的miRNA(miR-483-5p、miR-210-3p、miR-21-5p)以及两个对照(miR-16-5p、cel-miR-39-3p)。qPCR和dPCR结果在K2-和K3-EDTA样本中显示出不同的相关性,就ΔCt值而言,K2表现更好。此外,观察到两种方法之间与低或高miRNA表达相关的比例偏差。在qPCR测量中,K3-EDTA样本显示出更大的标准差,尤其是对于cel-miR-39。虽然K2-和K3-EDTA之间仅miR-483-5p的原始Ct值不同,但除miR-483-5p外,所有miRNA的ΔCt值均显示出统计学上的显著差异。dPCR结果不受抗凝剂选择的影响。总之,这是第一项表明dPCR和qPCR结果在循环miRNA方面不易互换的研究,特别是对于丰富或罕见的miRNA,这使得交叉验证研究具有挑战性。K2-和K3-EDTA可能会影响qPCR结果,强调了标准化方案的必要性。基于共识的方法可以提高可重复性,增强基于miRNA的生物标志物在肾上腺皮质肿瘤诊断中的效用。